Multiplex Immunoassay Troubleshooting Guide for Low-Abundance Biomarkers

Multiplex immunoassays allow laboratories to measure multiple proteins, cytokines, growth factors and other biomarkers from the same biological sample. That efficiency is particularly valuable in translational research, drug development and biomarker profiling. The analytical challenge becomes much greater, however, when one or more targets are present at concentrations close to the lower end of the assay’s usable range.

A weak signal is not automatically evidence that a biomarker is absent. The observed result may reflect genuinely low abundance, matrix suppression, nonspecific binding, cross-reactivity, antibody performance, sample degradation, dilution effects, calibration problems or an instrument and workflow issue. In a multiplex assay, the pattern of the failure provides important diagnostic information: if every analyte performs poorly, the cause is likely different from a situation in which only one biomarker fails while the rest of the panel performs normally.

The distinction between detection and reliable quantitation is especially important. A method may produce a measurable signal at a concentration near its limit of detection (LoD), while precision, recovery or reproducibility at that concentration remains inadequate for quantitative reporting. CLSI EP17 specifically addresses the evaluation and interpretation of the limit of blank (LoB), limit of detection and limit of quantitation (LoQ).

Matrix effects add another layer of complexity. Serum and plasma contain proteins, lipids, endogenous antibodies and other components capable of altering immunoassay responses. Published work on multiplex cytokine assays has demonstrated matrix inhibition, donor-to-donor variability and nonlinear dilution behavior, with some effects differing between serum and plasma and among individual cytokines.

The most effective troubleshooting strategy is therefore not to increase assay sensitivity indiscriminately. Instead, laboratory teams should identify the observed failure pattern, isolate the likely source experimentally, change one variable at a time and determine whether the resulting method is fit for the intended application.

Start by Defining What “Poor Performance” Actually Looks Like

Low signal is not always the same as low biomarker concentration

When a low-abundance biomarker produces a weak or undetectable result, several explanations are possible:

• The endogenous concentration is genuinely low.
• The analyte is below the assay’s reliable quantitative range.
• A matrix component suppresses the assay response.
• The target has degraded during collection, processing or storage.
• The antibody pair has inadequate affinity or specificity for the target in the sample matrix.
• An interfering substance is altering the immunochemical reaction.
• The sample dilution is inappropriate.
• Calibration or standard preparation is incorrect.
• Instrument, washing, incubation or pipetting performance is compromised.

These possibilities cannot be distinguished from a single concentration value alone.

For example, if a cytokine is reported below the assay’s detection threshold, it is tempting to interpret the result as “not present.” Analytically, that conclusion may be too strong. A sample can contain the biomarker while producing insufficient signal for reliable detection or quantitation under the selected assay conditions.

This distinction becomes particularly important when comparing treatment groups. If a treatment-associated decrease moves a biomarker toward the analytical floor, an apparent biological change may partly reflect deterioration in measurement performance.

Separate LoB, LoD, LoQ and the reportable range

The terms used to describe assay sensitivity should not be treated as interchangeable.

Limit of blank (LoB) describes the upper boundary of expected results when testing samples that contain no analyte. It helps characterize background behavior.

Limit of detection (LoD) describes the lowest amount of analyte that can be distinguished from the absence of analyte with a defined level of confidence.

Limit of quantitation (LoQ) goes further by addressing whether the analyte can be quantified with acceptable analytical performance.

For practical biomarker work, the lower limit of quantitation (LLOQ) is often more useful than an advertised LoD because researchers generally need a concentration that can be measured with acceptable precision and accuracy, not merely a signal that is statistically distinguishable from blank.

CLSI EP17 provides guidance for evaluating LoB, LoD and LoQ and emphasizes appropriate documentation and interpretation of detection capability.

A useful rule is:

A detectable biomarker is not necessarily a reliably quantifiable biomarker.

Establish the expected concentration range before changing the assay

Before modifying sample dilution, reagent concentrations or incubation conditions, compare the expected biological concentration with:

• The assay’s LLOQ
• The validated calibration range
• The required sample dilution
• Expected recovery
• Low-end precision
• QC performance

If the biological concentration is consistently below the method’s reliable quantitative range, repeatedly optimizing the existing assay may not solve the fundamental problem.

The appropriate question is not simply, “Can the assay detect this biomarker?” It is, “Can the assay measure this biomarker with performance suitable for the study’s purpose?”

Use the Pattern of the Failure to Narrow the Cause

The first diagnostic step should be to classify the failure.

When most analytes show weak signal

If many or all analytes in a multiplex panel show unexpectedly weak responses, begin with the shared components of the workflow.

Review:

• Reagent preparation and expiration
• Reagent storage and freeze-thaw history
• Standard preparation
• Incubation time and temperature
• Detection reagent preparation
• Plate or bead preparation
• Washing efficiency
• Pipetting and dispensing
• Instrument calibration and settings
• Calibration-curve acceptance
• Positive and negative controls

A global failure pattern is less consistent with an isolated antibody-pair problem and more suggestive of something common to the workflow.

When only one or two biomarkers perform poorly

An analyte-specific failure points in a different direction.

Investigate:

• Antibody-pair performance
• Target abundance
• Epitope accessibility
• Target stability
• Cross-reactivity
• Matrix sensitivity of that analyte
• Calibration-curve behavior
• Analyte-specific interference

A multiplex panel should never be assumed to provide identical analytical performance for every target. Each analyte is effectively its own analytical measurement embedded within a shared platform.

When controls perform well but biological samples do not

This pattern should move matrix effects higher on the troubleshooting list.

Compare assay behavior using:

• Standards prepared in assay diluent
• Representative biological matrix
• Spiked biological samples
• Serially diluted samples
• Appropriate negative controls

If standards behave well but biological samples show poor recovery or nonparallel dilution, the assay may be functioning correctly while the sample matrix is compromising measurement.

Studies of multiplex cytokine assays have demonstrated precisely this type of behavior: serum and plasma can inhibit cytokine measurements, the magnitude can vary between donors and analytes, and dilution does not necessarily produce a simple linear response.

Matrix Effects Are Often the First Suspect for Low-Abundance Targets

Why serum and plasma can suppress low-level signals

Biological samples are analytically complex. Serum and plasma contain abundant proteins, lipids, salts, immunoglobulins, endogenous antibodies and other substances that can influence antibody binding or signal generation.

For a high-abundance analyte, moderate signal suppression may still leave sufficient response above background. For a low-abundance biomarker, the same suppression can push the measured response toward the analytical floor.

Matrix effects can manifest as:

• Reduced signal
• Elevated background
• Poor spike recovery
• Unexpected dilution behavior
• Sample-to-sample variability
• Different performance between serum and plasma

Importantly, matrix effects are not necessarily uniform across a multiplex panel. One cytokine may exhibit strong suppression while another is comparatively unaffected.

A study comparing serum and plasma in multiplex cytokine assays found increased nonspecific background in serum and demonstrated inhibition of many cytokine measurements in both matrices. The study also observed donor variability and nonlinear dilution effects.

How to recognize matrix interference experimentally

A useful investigation combines several experiments rather than relying on one measurement.

Spike recovery asks whether a known quantity of analyte added to a biological sample can be recovered at the expected level.

Serial dilution examines whether the measured concentration behaves predictably as the sample is diluted.

Dilutional parallelism compares the response curve of a diluted sample with the calibration curve. Nonparallel behavior can indicate matrix effects, analyte-specific behavior or other assay limitations.

Matrix comparison can be useful when the study involves more than one specimen type, such as serum and EDTA plasma.

Poor recovery, sample-dependent suppression and nonparallel dilution should prompt further investigation rather than automatic reporting of the calculated concentration.

A single acceptable spike-recovery result should also not be treated as complete proof of matrix compatibility. Matrix effects can vary by donor, analyte concentration, sample type and assay conditions.

Choosing sample dilution without losing low-abundance biomarkers

Dilution creates an important trade-off.

Diluting a sample can reduce the concentration of interfering matrix components and sometimes improve assay performance. However, it also reduces the concentration of the target biomarker.

For a low-abundance analyte, excessive dilution can move the concentration below the LLOQ.

This is why a single dilution factor should not automatically be applied to every analyte in a multiplex panel. Different targets can respond differently to dilution. Published multiplex cytokine data have shown that dilution can partially reduce matrix inhibition while simultaneously producing nonlinear and analyte-dependent responses.

A practical approach is to evaluate several dilution levels during method development and determine which dilution provides acceptable recovery, parallelism, precision and quantitation for the intended biomarker range.

When matrix matching becomes necessary

If standards prepared in assay diluent behave substantially differently from analytes in biological samples, matrix matching may need to be considered.

Depending on the platform, this could involve validated matrix-matched standards or an alternative diluent demonstrated to reduce matrix effects.

However, matrix modification should not be assumed to improve the assay simply because it increases signal. Any change should be evaluated against recovery, precision, specificity and calibration performance.

Check Whether the Multiplex Panel Itself Is Creating Analytical Interference

Antibody cross-reactivity between panel targets

Multiplex assays bring multiple antibody pairs and analytes into the same analytical environment. Antibodies are selected for specificity, but structurally related proteins can create opportunities for unintended interactions.

Potential concerns include:

• Related cytokines
• Growth factors
• Protein isoforms
• Homologous protein families
• Shared epitopes
• Unexpected interactions with assay reagents

Cross-reactivity may produce elevated signal, increased background or distorted calibration behavior. It can also cause an apparently changing concentration of one analyte when another component of the biological system changes.

The key diagnostic question is whether the problematic behavior follows the analyte, the sample, or the multiplex configuration.

Competition and analyte interactions within a multiplex reaction

A multiplex assay is not simply several singleplex assays operating independently. Multiple capture and detection reagents coexist within the same reaction environment.

Changes to a panel can therefore alter analytical behavior. Adding, removing or replacing an analyte may expose previously unnoticed cross-reactivity or reagent interactions.

For this reason, performance data for one panel configuration should not automatically be transferred to another without verification.

Detecting a problematic antibody pair

If one analyte consistently performs poorly, compare it with:

• A validated singleplex assay
• An alternative antibody pair, where available
• A known positive control
• An orthogonal analytical method

An orthogonal method is particularly valuable when the biological question is important enough that immunoassay-specific uncertainty could materially affect the conclusion.

If the analyte performs adequately in singleplex but poorly in multiplex, the multiplex configuration deserves closer investigation. If it performs poorly in both formats, the problem may be more fundamental to antibody specificity, target stability or the biomarker itself.

Investigate Nonspecific Binding and High Background Before Increasing Signal

Common sources of elevated background

High background can arise from:

• Inadequate washing
• Nonspecific antibody binding
• Contaminated wells
• Cross-well contamination
• Inappropriate blocking conditions
• Reagent carryover
• Matrix-associated interference
• Bead or plate handling problems
• Instrument or fluidics problems

Manufacturer troubleshooting documentation should be consulted for platform-specific causes because wash requirements, bead handling, calibration and instrument maintenance vary between systems.

Why high background is especially damaging to low-abundance biomarkers

Suppose a low-abundance biomarker produces only a small increase above blank. A modest increase in background can consume much of that analytical separation.

It is therefore useful to distinguish:

• High absolute signal: the measured response is large.
• High background: the blank or negative-control response is elevated.
• Poor signal-to-background ratio: the target response does not separate sufficiently from background.

Increasing detection intensity may increase both target signal and background. If nonspecific binding is the underlying problem, simply making the assay “more sensitive” may make interpretation worse rather than better.

Corrective experiments

Begin with the basics:

1. Review blank and negative-control wells.
2. Confirm washing performance.
3. Check reagent preparation and carryover.
4. Compare matrix and assay-diluent conditions.
5. Examine whether the background is global or analyte-specific.
6. Inspect plate or bead handling and instrument performance.

The objective is to determine whether background originates from the assay chemistry, the biological matrix or the workflow.

Rule Out Antibody and Target-Specific Problems

Antibody affinity and epitope accessibility

Even a highly sensitive assay can perform poorly if the antibody pair does not recognize the target effectively in its biological form.

Potential causes include:

• Epitope masking
• Protein conformation
• Binding to protein complexes
• Post-translational modifications
• Protein fragmentation
• Differences between recombinant standards and endogenous protein

This creates an important analytical distinction: total protein abundance is not necessarily equivalent to immunoreactive target abundance.

A recombinant calibrator may be readily recognized by the antibody pair while an endogenous protein in serum or plasma has a different conformation or is partially complexed.

Target degradation and sample instability

Low-abundance biomarkers are particularly vulnerable to modest losses during sample handling.

Review:

• Time between collection and processing
• Centrifugation and separation procedures
• Storage temperature
• Aliquoting practices
• Freeze-thaw history
• Long-term storage
• Temperature excursions
• Proteolytic degradation

If historical samples show lower concentrations than freshly prepared controls, the issue may be sample stability rather than assay sensitivity.

Lot-to-lot reagent variability

A sudden shift in biomarker concentrations that coincides with a reagent-lot change deserves investigation.

Useful controls include:

• Retained reference samples
• Historical QC materials
• Lot-comparison experiments
• Trend charts for control performance

Lot acceptance criteria should be established before introducing a new reagent lot into a longitudinal biomarker program.

Otherwise, a reagent-related shift can be mistaken for a biological change.

Check for Immunoassay Interferences That Can Mimic Biomarker Changes

Heterophilic antibodies and human anti-animal antibodies

Endogenous antibodies can interfere with immunometric assays by interacting with assay antibodies or creating unintended bridges between capture and detection components.

The result may be an unexpectedly high or, in some circumstances, an unexpectedly low result.

Suspicious patterns include:

• Results inconsistent with the biological context
• Strong sample-specific effects
• Poor reproducibility
• Unexpectedly high concentrations
• Discordance between two assay methods

Heterophilic antibody interference is a recognized vulnerability of immunometric assays, and published studies describe the use of blocking approaches and alternative assay designs as possible investigative or mitigation strategies.

When interference is suspected, laboratories can consider appropriate blocking experiments, alternative assay formats or orthogonal testing. Blocking results should themselves be interpreted carefully because a change after blocking establishes susceptibility to an interfering mechanism but does not necessarily identify its precise biochemical source.

Biotin interference in biotin-streptavidin assay formats

Some immunoassays use biotin-streptavidin chemistry as part of their assay architecture. In these systems, high circulating biotin can interfere with measurement.

The direction of interference depends on assay design. In general, excess biotin can produce different effects in competitive versus sandwich formats, so laboratories should not assume that biotin will always increase or always decrease a result.

The first question is therefore whether the assay actually uses a biotin-streptavidin component and whether the platform documentation identifies susceptibility.

When relevant, laboratories should review sample history and potential exposure to high-dose biotin supplementation, follow platform-specific recommendations and use appropriate confirmatory testing. AACC guidance emphasizes that the concentration required to cause interference varies by assay and manufacturer.

Other sample-associated interference

Other potential contributors include:

• Hemolysis
• Lipemia
• Hyperbilirubinemia
• Endogenous antibodies
• Paraproteins
• Drug-related interference
• Collection-tube components

Not every possible interferent will affect every assay. The appropriate approach is to distinguish demonstrated assay-specific interference from theoretical possibilities.

A useful review of immunoassay interference notes that cross-reacting substances, endogenous antibodies, pre-analytical factors, matrix effects and equipment-related factors can all contribute to erroneous results.

Do Not Ignore Sample Collection and Pre-Analytical Variation

Collection tube and specimen type

Serum and plasma should not automatically be treated as interchangeable.

Consider:

• Serum versus plasma
• EDTA versus heparin or other anticoagulants
• Tube additives
• Collection procedures
• Consistency between study sites

If a biomarker study changes specimen type during the project, the analytical consequences should be evaluated rather than assuming that the resulting values remain directly comparable.

Processing and storage

Standardize:

• Time to centrifugation
• Centrifugation conditions
• Sample separation
• Aliquot volume
• Storage temperature
• Freeze-thaw exposure
• Shipping conditions

A robust assay cannot compensate for uncontrolled sample degradation.

Biological variability that can resemble analytical variability

Not every change between samples is an assay problem.

Biomarker concentrations can change because of:

• Circadian biology
• Disease activity
• Treatment timing
• Acute inflammatory events
• Individual biological variability

This distinction matters because analytical troubleshooting and biological interpretation answer different questions. The laboratory should first establish whether the method is behaving consistently before attributing observed differences to disease biology or treatment response.

Calibration Curves Can Reveal More Than a Single Concentration Value

What a problematic low-end curve can indicate

The calibration curve can reveal problems that are hidden by looking only at calculated sample concentrations.

A poorly behaved low end may indicate:

• Excessive background
• Poor standard preparation
• Insufficient sensitivity
• Reagent instability
• Inappropriate curve fitting
• Poor standard recovery

Inspect the lowest calibrators rather than relying only on whether software successfully generates a fitted curve.

When the lowest standards become unreliable

A software-generated concentration is not automatically a valid quantitative result.

At the low end, examine:

• Replicate precision
• Recovery
• Back-calculated concentrations
• Blank behavior
• QC performance
• Run-to-run consistency

If the lowest calibrators show excessive variability, the nominal LLOQ may not be appropriate for the intended study, even if the software can mathematically interpolate sample values below that point.

Nonlinearity and poor dilutional parallelism

Serial dilution is useful because it can reveal whether a sample behaves like the calibrator.

If a sample does not show appropriate dilutional parallelism, possible causes include matrix interference, nonlinear assay behavior, target instability or analyte-specific effects.

The laboratory should avoid automatically interpreting every nonlinear dilution pattern as biological behavior. In an immunoassay, analytical nonlinearity is often the more immediate question.

A Practical Troubleshooting Workflow for Low-Abundance Multiplex Biomarkers

Step 1 — Confirm the failure pattern

Ask:

• Is the problem global or analyte-specific?
• Do standards perform correctly?
• Are QC samples acceptable?
• Is the issue limited to biological samples?
• Is the failure reproducible across runs?
• Does the same sample behave differently at different dilutions?

This classification prevents laboratories from changing assay chemistry before understanding the problem.

Step 2 — Confirm assay range and detection capability

Compare the expected biomarker concentration with:

• LLOQ
• Calibration range
• Low-end precision
• QC performance
• Required dilution

If the expected concentration is consistently below reliable quantitation, the problem may be one of method suitability rather than method execution.

Step 3 — Test for matrix effects

Use an appropriate combination of:

• Spike recovery
• Serial dilution
• Dilutional parallelism
• Matrix comparison
• Matrix-matched controls where justified

A matrix effect becomes more convincing when several independent observations point in the same direction.

Step 4 — Investigate interference and cross-reactivity

Depending on the assay architecture, evaluate:

• Heterophilic antibody susceptibility
• Relevant biotin interference
• Cross-reactivity
• Singleplex versus multiplex performance
• Alternative antibody pairs
• Orthogonal measurement

Step 5 — Review pre-analytical and reagent variables

Check:

• Sample collection
• Processing
• Storage
• Freeze-thaw history
• Reagent lot
• Standard preparation
• Instrument calibration
• Washing
• Pipetting
• Operator-dependent steps

Step 6 — Change one variable at a time

Simultaneously changing dilution, reagent concentration, incubation time and washing conditions may improve the result but make the underlying cause impossible to identify.

A controlled troubleshooting experiment should therefore define:

1. The variable being changed
2. The reason for changing it
3. The expected effect
4. The acceptance criterion
5. The result
6. The next decision

This creates a traceable troubleshooting record and prevents an optimized protocol from becoming a collection of undocumented modifications.

When Optimization Is Appropriate—and When the Assay Should Be Replaced

Signs that optimization may solve the problem

Optimization is reasonable when the underlying method is fundamentally sound and the failure is associated with a manageable variable, such as:

• A reproducible matrix effect that improves with validated dilution
• Consistent recovery after appropriate sample preparation
• Stable calibration and QC behavior
• Acceptable low-end precision after optimization
• A known pre-analytical weakness that can be controlled

The goal should be measurable improvement against predefined acceptance criteria, not simply higher signal.

Signs that the platform may not be fit for purpose

Consider reassessment when:

• The biomarker consistently falls below reliable quantitation.
• Recovery remains poor across relevant biological matrices.
• Sample-dependent interference is severe.
• Inter-run variability remains unacceptable.
• Analyte-specific cross-reactivity persists.
• The multiplex result disagrees substantially with an appropriate orthogonal method.
• Optimization repeatedly improves one analyte while compromising others.

At this point, further optimization may consume time without addressing the fundamental analytical limitation.

When to consider an alternative analytical technology

Depending on the biological question, alternatives can include:

• Singleplex immunoassays
• Higher-sensitivity digital immunoassay platforms
• Electrochemiluminescence-based assays
• Targeted mass spectrometry
• Other orthogonal analytical technologies

The appropriate choice should be based on fit-for-purpose performance, not the lowest advertised detection limit.

For example, a platform with an extremely low theoretical LoD may still be unsuitable if matrix effects, precision or recovery are unacceptable at the concentrations encountered in the actual study.

Validation and Documentation Before Using Troubleshooting Changes in a Study

Define acceptance criteria before optimization

A troubleshooting exercise should establish what “good enough” means before experimental changes are introduced.

Depending on intended use, relevant characteristics may include:

• Precision
• Accuracy or recovery
• Dilutional linearity
• Selectivity
• Specificity
• Sensitivity
• Stability
• Matrix compatibility
• QC performance
• Calibration performance

The exact acceptance criteria should reflect the assay’s purpose, platform and development stage.

Document assay changes and their effect

Maintain version-controlled records of:

• Protocol changes
• Reagent lots
• Calibration materials
• Sample preparation
• Dilution factors
• Instrument configuration
• Acceptance criteria
• Pre- and post-optimization results

Material changes in assay conditions can affect comparability. Data generated before and after a major method modification should therefore not automatically be pooled without evaluating whether the analytical change affects interpretation.

Consider regulatory expectations when results support development decisions

Regulatory expectations depend on the intended use of the assay.

FDA’s M10 Bioanalytical Method Validation and Study Sample Analysis provides recommendations for bioanalytical methods used to generate data supporting regulatory submissions, including ligand-binding assays. However, M10 explicitly states that bioanalysis of biomarkers is outside its scope.

That distinction is important for biomarker programs. In April 2026, FDA issued a separate final guidance specifically addressing Bioanalytical Method Validation for Biomarkers, including methods used to evaluate biomarker concentrations in applicable nonclinical and clinical development contexts.

Laboratories should therefore identify the applicable regulatory and study-specific framework rather than citing M10 as a universal biomarker-validation standard.

A Compact Root-Cause Matrix for Laboratory Teams

This matrix is a troubleshooting aid, not a substitute for assay-specific validation. A single observed pattern can have more than one cause, and confirmation experiments should be selected according to the assay architecture and intended use.

How High-Sensitivity Biomarker Quantitation Fits Into the Bigger Picture

The analytical challenges described here become increasingly important as biomarker programs move toward smaller concentration differences and earlier biological signals. For researchers working with low-concentration disease biomarkers, broader advances in high-sensitivity biomarker quantitation illustrate why analytical sensitivity must be considered alongside specificity, precision and matrix compatibility.

Multiplex protein measurements can also become one component of broader biomarker-discovery strategies. When researchers combine protein measurements with genomic, transcriptomic or spatial information, spatial multi-omics approaches can provide complementary information about where molecular changes occur within diseased tissue. Such approaches do not replace careful immunoassay validation, but they demonstrate the broader role of reliable biomarker measurements within translational research.

Frequently Asked Questions

Why are low-abundance biomarkers difficult to measure with multiplex immunoassays?

Low-abundance biomarkers generate signals close to the assay’s background and lower quantitative range. Matrix suppression, nonspecific binding, antibody performance, target degradation and assay interference can further reduce effective signal. Consequently, an analyte may be detectable without being reliably quantifiable.

What is the difference between LOD and LLOQ in a multiplex immunoassay?

The LoD addresses whether an analyte can be distinguished from blank, while the LoQ concerns whether it can be quantified with acceptable analytical performance. For quantitative biomarker studies, the LLOQ is therefore generally more informative than the LoD alone. CLSI EP17 provides guidance for evaluating detection capability.

How can matrix effects be detected in a multiplex immunoassay?

Common approaches include spike recovery, serial dilution, dilutional parallelism and comparison of relevant sample matrices. Poor recovery or nonparallel dilution suggests that sample components may be affecting the assay. Because matrix effects can vary between analytes and donors, more than one experiment is usually needed.

Why does diluting a sample sometimes improve multiplex immunoassay results?

Dilution can reduce the concentration of inhibitory matrix components and sometimes improve assay response. However, dilution also lowers the biomarker concentration, which can push a low-abundance target below the LLOQ. Multiplex cytokine studies have shown that dilution effects can be nonlinear and analyte-dependent.

What should be done when one biomarker performs poorly while the rest of a multiplex panel works?

Start with analyte-specific causes: antibody-pair performance, target stability, cross-reactivity, matrix sensitivity and calibration behavior. Compare the analyte in singleplex, with appropriate controls or using an orthogonal method where justified. A single-analyte failure does not necessarily indicate that the entire multiplex platform is unsuitable.

Conclusion

Troubleshooting low-abundance biomarkers in multiplex immunoassays is fundamentally an exercise in identifying the source of analytical uncertainty, not simply increasing assay sensitivity.

Three principles provide a practical starting point:

1. Establish whether the biomarker is actually within the assay’s reliable quantitative range. A low LoD does not guarantee reliable quantitation at the low end; LLOQ, precision, recovery and reproducibility matter.
2. Investigate matrix, interference, antibody and pre-analytical effects systematically. Spike recovery, dilutional behavior, controls, singleplex comparisons and orthogonal methods can help distinguish among competing explanations.
3. Know when to stop optimizing. If acceptable recovery, precision and specificity cannot be achieved across the relevant biological matrix and concentration range, the assay may not be fit for purpose.

For translational research, biomarker development and drug-development programs, the strongest analytical method is not necessarily the one with the lowest advertised detection limit. It is the method that can produce sufficiently reliable measurements in the actual samples, concentration range and decision context in which the data will be used.

That fit-for-purpose principle becomes particularly important when biomarker measurements influence development decisions, mechanistic conclusions or clinical research. A well-documented troubleshooting process can reveal whether a multiplex assay needs optimization, tighter sample control, a redesigned analyte assay or a fundamentally different analytical technology.

Sources and technical references

The analytical principles discussed above are supported by CLSI guidance on detection capability, peer-reviewed literature on multiplex serum/plasma matrix effects and immunoassay interference, and current FDA guidance relevant to bioanalytical and biomarker methods. CLSI EP17 covers LoB, LoD and LoQ; published multiplex cytokine research demonstrates matrix-dependent and nonlinear dilution behavior; and FDA’s 2026 biomarker guidance provides a specific regulatory framework for applicable biomarker bioanalytical methods.